NASDAQ · CLRB
Healthcare · Biotechnology
$2.35
Up+$0.03 (+1.29%)
Updated Sep 17, 2026, 3:09 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CLRB closed at $2.35 after 20 trading sessions, down 10.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $2.32 | $2.39 | $2.32 | $2.35 | 73.03K |
| Sep 15, 2026 | $2.31 | $2.34 | $2.28 | $2.32 | 33.37K |
| Sep 14, 2026 | $2.33 | $2.45 | $2.29 | $2.31 | 65.75K |
| Sep 11, 2026 | $2.35 | $2.40 | $2.31 | $2.31 | 38.39K |
| Sep 10, 2026 | $2.35 | $2.40 | $2.35 | $2.37 | 18.89K |
| Sep 9, 2026 | $2.41 | $2.45 | $2.35 | $2.365 | 44.38K |
| Sep 8, 2026 | $2.46 | $2.47 | $2.375 | $2.41 | 27.56K |
| Sep 4, 2026 | $2.33 | $2.40 | $2.33 | $2.37 | 26.58K |
| Sep 3, 2026 | $2.39 | $2.44 | $2.34 | $2.35 | 70.01K |
| Sep 2, 2026 | $2.46 | $2.50 | $2.42 | $2.43 | 48.77K |
| Sep 1, 2026 | $2.48 | $2.54 | $2.45 | $2.46 | 46.43K |
| Aug 31, 2026 | $2.52 | $2.55 | $2.49 | $2.51 | 17.29K |
| Aug 28, 2026 | $2.55 | $2.55 | $2.51 | $2.53 | 23.84K |
| Aug 27, 2026 | $2.57 | $2.57 | $2.52 | $2.54 | 10.32K |
| Aug 26, 2026 | $2.46 | $2.59 | $2.46 | $2.54 | 13.2K |
| Aug 25, 2026 | $2.59 | $2.60 | $2.50 | $2.54 | 16.67K |
| Aug 24, 2026 | $2.56 | $2.5899 | $2.50 | $2.52 | 23.17K |
| Aug 21, 2026 | $2.5999 | $2.60 | $2.50 | $2.59 | 26.65K |
| Aug 20, 2026 | $2.6199 | $2.62 | $2.50 | $2.59 | 32.8K |
| Aug 19, 2026 | $2.61 | $2.70 | $2.61 | $2.62 | 56.24K |
The latest Smart Investors Daily articles mentioning CLRB.
CLRB research
Company profile and research snapshot.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 10, 2026 | Maxim Group | Buy | — |
| May 14, 2025 | Maxim Group | Hold | — |
| Dec 11, 2024 | Oppenheimer | Perform | — |
| Nov 19, 2024 | Oppenheimer | Outperform | — |
| Oct 11, 2024 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Aug 18, 2026
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy August 18, 2026...
SeekingAlpha · Aug 18, 2026
2026-08-18. The following slide deck was published by Cellectar Biosciences, Inc.
Benzinga · Aug 14, 2026
- SEC Filing
Benzinga · Aug 14, 2026
- SEC Filing
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CLRB.
